XTL Biopharmaceuticals Ltd. XTLB
Set alert
1.61 USD -0.15 -8.52%
At close · Oct 30
1.79 +0.18 +11.02%
After hours · Oct 30, 4:00 PM ET
1.61 Day range 1.69
1.61 52-week range 4.32
- YTD
- -30.60%
- 1 year
- -62.73%
- Open
- 1.65
- Prev close
- 1.76
- Mkt cap
- 3.96M
- Vol
- 8.60K
- Avg vol
- 7.97K
- EPS
- -0.36
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 1.61
- High
- 1.69
- Forward P/E
- 0.00
- Beta
- 1.00
- Short ratio
- 3.35
- Inst. own
- 1.92%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Dec 25, 2024
- 50-d avg
- 1.84
- 200-d avg
- 2.32
- 1y target
- 0.00
2Y chart
Events in this range
- Mar 25, 2026Split: 1 for 4
Signals (86)
| Name | Date | Ago |
|---|---|---|
| MACD: Sell Signal | Oct 30, 2026 | 2 days ago |
| MACD: Buy Signal | Oct 19, 2026 | 1 week ago |
| SMA: Bearish | Aug 24, 2026 | 2 months ago |
| MACD: Sell Signal | Aug 20, 2026 | 2 months ago |
| SMA: Bearish | Aug 19, 2026 | 2 months ago |
| SMA: Bullish | Aug 18, 2026 | 2 months ago |
| SMA: Bullish | Aug 18, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 18, 2026 | 2 months ago |
| SMA: Bearish | Aug 17, 2026 | 2 months ago |
| SMA: Bullish | Aug 12, 2026 | 2 months ago |
| SMA: Bearish | Aug 11, 2026 | 2 months ago |
| MACD: Sell Signal | Jul 22, 2026 | 3 months ago |
| SMA: Bullish | Jul 2, 2026 | 4 months ago |
| SMA: Bearish | Jul 1, 2026 | 4 months ago |
| SMA: Bullish | Jun 30, 2026 | 4 months ago |
| SMA: Bearish | Jun 25, 2026 | 4 months ago |
| SMA: Bullish | Jun 22, 2026 | 4 months ago |
| MACD: Buy Signal | Jun 15, 2026 | 4 months ago |
| SMA: Bearish | May 19, 2026 | 5 months ago |
| SMA: Bullish | May 18, 2026 | 5 months ago |
| SMA: Bearish | May 15, 2026 | 5 months ago |
| SMA: Bullish | May 13, 2026 | 5 months ago |
| SMA: Bearish | May 12, 2026 | 5 months ago |
| SMA: Bullish | May 11, 2026 | 5 months ago |
| MACD: Sell Signal | May 8, 2026 | 5 months ago |
| SMA: Bearish | May 7, 2026 | 5 months ago |
| RSI: Overbought | May 4, 2026 | 6 months ago |
| SMA: Bullish | Apr 29, 2026 | 6 months ago |
| RSI: Overbought | Apr 29, 2026 | 6 months ago |
| MACD: Buy Signal | Mar 24, 2026 | 7 months ago |
| SMA: Bearish | Feb 23, 2026 | 8 months ago |
| SMA: Bullish | Feb 18, 2026 | 8 months ago |
| SMA: Bearish | Feb 17, 2026 | 8 months ago |
| MACD: Sell Signal | Feb 11, 2026 | 8 months ago |
| MACD: Buy Signal | Feb 4, 2026 | 9 months ago |
| MACD: Sell Signal | Jan 29, 2026 | 9 months ago |
| SMA: Bullish | Jan 13, 2026 | 9 months ago |
| MACD: Buy Signal | Jan 8, 2026 | 9 months ago |
| RSI: Oversold | Dec 31, 2025 | 10 months ago |
| MACD: Sell Signal | Dec 29, 2025 | 10 months ago |
| RSI: Oversold | Dec 29, 2025 | 10 months ago |
| MACD: Buy Signal | Dec 1, 2025 | 11 months ago |
| RSI: Oversold | Nov 20, 2025 | 11 months ago |
| SMA: Bearish | Oct 17, 2025 | 1 year ago |
| MACD: Sell Signal | Oct 17, 2025 | 1 year ago |
| SMA: Bearish | Oct 16, 2025 | 1 year ago |
| SMA: Bullish | Oct 15, 2025 | 1 year ago |
| SMA: Bearish | Oct 13, 2025 | 1 year ago |
| RSI: Overbought | Oct 8, 2025 | 1 year ago |
| SMA: Bullish | Oct 7, 2025 | 1 year ago |
| SMA: Bullish | Oct 7, 2025 | 1 year ago |
| MACD: Buy Signal | Oct 7, 2025 | 1 year ago |
| MACD: Sell Signal | Sep 19, 2025 | 1 year ago |
| SMA: Bearish | Sep 10, 2025 | 1 year ago |
| SMA: Bearish | Sep 10, 2025 | 1 year ago |
| SMA: Bullish | Sep 9, 2025 | 1 year ago |
| SMA: Bullish | Sep 9, 2025 | 1 year ago |
| MACD: Buy Signal | Sep 5, 2025 | 1 year ago |
| SMA: Bearish | Aug 18, 2025 | 1 year ago |
| SMA: Bullish | Aug 11, 2025 | 1 year ago |
| SMA: Bearish | Aug 8, 2025 | 1 year ago |
| MACD: Sell Signal | Jul 29, 2025 | 1 year ago |
| SMA: Bullish | Jul 3, 2025 | 1 year ago |
| SMA: Bearish | Jun 25, 2025 | 1 year ago |
| SMA: Bullish | Jun 24, 2025 | 1 year ago |
| MACD: Buy Signal | Jun 24, 2025 | 1 year ago |
| MACD: Sell Signal | Jun 20, 2025 | 1 year ago |
| SMA: Bearish | Jun 10, 2025 | 1 year ago |
| SMA: Bullish | Jun 9, 2025 | 1 year ago |
| MACD: Buy Signal | Jun 2, 2025 | 1 year ago |
| SMA: Bearish | May 13, 2025 | 1 year ago |
| MACD: Sell Signal | May 9, 2025 | 1 year ago |
| SMA: Bullish | Apr 24, 2025 | 1 year ago |
| SMA: Bearish | Apr 23, 2025 | 1 year ago |
| SMA: Bullish | Apr 22, 2025 | 1 year ago |
| MACD: Buy Signal | Mar 27, 2025 | 1 year ago |
| MACD: Sell Signal | Mar 18, 2025 | 1 year ago |
| MACD: Buy Signal | Mar 14, 2025 | 1 year ago |
| MACD: Sell Signal | Feb 19, 2025 | 1 year ago |
| MACD: Buy Signal | Feb 12, 2025 | 1 year ago |
| SMA: Bearish | Jan 27, 2025 | 1 year ago |
| SMA: Bullish | Jan 22, 2025 | 1 year ago |
| SMA: Bearish | Jan 15, 2025 | 1 year ago |
| MACD: Sell Signal | Jan 14, 2025 | 1 year ago |
| MACD: Buy Signal | Dec 24, 2024 | 1 year ago |
| RSI: Oversold | Dec 17, 2024 | 1 year ago |
Key statistics
- Market cap
- 9.59M
- Enterprise value
- 782.33M
- Trailing P/E
- 0.00
- Forward P/E
- 0.00
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 352.00
- EPS (TTM)
- -0.03
- Beta
- 1.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- 0
- Total cash
- 2.34M
- Total debt
- 0
- Return on equity
- -13.07%
- Shares outstanding
- 5.45M
- Short % of float
- 0.00%
- 50-day average
- 1.84
- 200-day average
- 2.32
Analyst view
Consensus: none
Price target (mean) 0.00
Next earnings
Dec 25, 2024
Expected Dec 25, 2024. Consensus EPS estimate 0.00.
Financials — quick view
XTLB Revenue — annual 0
XTLB Net income — annual -6.97M
XTLB EPS — annual -3.20
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Dec 25, 2024 | Sep 1, 2024 | 0.00 | — | — | — |
| Oct 3, 2024 | Jun 1, 2024 | 0.00 | — | — | — |
| May 13, 2024 | Mar 1, 2024 | 0.00 | 0.10 | — | — |
| Nov 15, 2023 | Sep 1, 2023 | 0.00 | -0.04 | — | — |
| Aug 10, 2023 | Jun 1, 2023 | 0.00 | -0.07 | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| May 8, 2015 | HC Wainwright & Co. | init | — | Buy |
About XTL Biopharmaceuticals Ltd.
XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases in Israel. Its lead drug candidate is hCDR1, a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. It has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was incorporated in 1993 and is headquartered in Ramat Gan, Israel.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Israel
- Website
- xtlbio.com
News
- Burning Rock Biotech (NASDAQ:BNR) and XTL Biopharmaceuticals (NASDAQ:XTLB) Critical Analysis
- XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB) Short Interest Update
- DBV Technologies (NASDAQ:DBVT) versus XTL Biopharmaceuticals (NASDAQ:XTLB) Financial Analysis
- 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- 12 Health Care Stocks Moving In Wednesday's Intraday Session
- XTL Completed the Acquisition of Psyga Bio Ltd.
- 12 Health Care Stocks Moving In Monday's After-Market Session
- 12 Health Care Stocks Moving In Monday's After-Market Session
Your note
Sign in to keep a note on XTLB — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Noked Israel Ltd. | 3.65% | 198,888 | 350.04K | Sep 29, 2024 |
| Morgan Stanley | 0.49% | 26,451 | 46.55K | Sep 29, 2024 |
| Rhumbline Advisers | 0.12% | 6,519 | 11.47K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity NASDAQ Composite Index Fund | 0.16% | 8,903 | 15.67K | Oct 30, 2024 |